IDH1 and acute myeloid leukemia: The use of CRh as a marker of response was implemented in the pivotal phase 3 ADMIRAL trial, comparing gilteritinib with salvage chemotherapy in FLT3mut+ R/R AML,20 and has also been implemented in the phase 1 trial of the IDH1 inhibitor, ivosidenib, in IDH1‐mutated R/R AML.25